期刊文献+

促红细胞生成素治疗慢性充血性心力衰竭临床研究 被引量:4

下载PDF
导出
摘要 目的分析在慢性充血性心力衰竭标准治疗的基础上加用促红细胞生成素(EPO)皮下注射的临床疗效。方法入选的70例患者随机分为EPO治疗组和对照组。治疗组(并用组)40例,对照组(常规治疗组)30例,进行对照分析。结果①EPO治疗组总有效率显著高于对照组,差异具有统计学意义(P<0.05)。②EPO治疗组治疗前后贫血指标及心功能指标的改善均优于对照组(P<0.05)。③EPO治疗组治疗后再住院率及死亡率均显著低于对照组(P<0.01)。④两组治疗后呋噻米、地高辛使用剂量下降人数比较,治疗组明显高于对照组(P<0.01),且未见明显不良反应。结论并用EPO治疗慢性充血性心力衰竭安全有效,心功能指标及运动耐力提高,降低了死亡率及总住院时间,改善了预后及生活质量。
作者 曹优文
出处 《临床和实验医学杂志》 2008年第3期87-88,共2页 Journal of Clinical and Experimental Medicine
  • 相关文献

参考文献5

二级参考文献23

  • 1郑法雷,李莉,谌贻璞,陈香美,王质刚,唐政,陆福明,王梅,于仲元.应用重组人红细胞生成素注射液(宁红欣)治疗肾性贫血的多中心临床试验报告[J].中国血液净化,2002,1(5):5-8. 被引量:16
  • 2美国NKF—K/DOQI工作组.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2003,6..
  • 3Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis, 1989,14(1) :14-18.
  • 4Ma J Z, Ebbcn J, Xiz H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol, 1999,10:610.
  • 5NKF-K/DOQI: Clinical Practice Guidelines, Guideline for anemia of chronic kidney of chronic kidney disease,2000, 24.
  • 6袁伟杰 何长民 等.血液透析的慢性并发症.肾脏替代治疗学[M].上海:上海科学技术文献出版社,1999.97.
  • 7王海燕.肾脏病学[M],第1版[M].北京:人民卫生出版社,1998.1396-1399.
  • 8Winearls CG. Recombinant erythropoietin : 10year of clinical experience[J].Nephrol Dial Transplant, 1998,13(Suppl 2) :3.
  • 9Jone MA, Kingswood JC, Dallyn PE, et al. Haemodynamic changes measured by transthoraic bioimpedance during treatment with recombinant human erythropoietin[J].Clin Exp Hypertens, 1996,18(1) : 51.
  • 10Ezekowitz JA,McAlister FA,Armstrong PW.Anemia is common in heart failure and is associated with poor outcomes[].Circulation.2003

共引文献49

同被引文献63

  • 1Komajda M.,Anker S.D.,Charlesworth A.,郭俊.新发贫血对慢性心力衰竭发病率和死亡率的影响:来自COMET研究的结果[J].世界核心医学期刊文摘(心脏病学分册),2006(12):26-27. 被引量:14
  • 2左建国,乔丙勋,丁书振,时晓红.美托洛尔治疗充血性心力衰竭的临床观察[J].临床医学,2005,25(5):25-26. 被引量:6
  • 3郭玲,王爱红,吕琳,鹿克风,孙永乐.EPO辅助治疗慢性心力衰竭合并贫血52例临床观察[J].山东医药,2007,47(5):57-58. 被引量:10
  • 4Caiola K,Cheng JW.Use of erythropoietin in heart failure management[J].Ann Pharmacother,2004,38 (12):2145 -2149.
  • 5Guglin ME,Koul D.Cardiovascular effects of erythropoietin:anemia and beyond[J].Cardiol Rev,2006,14 (4):200-204.
  • 6Bullard AJ,Yellon DM.Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro[J].Cardiovasc Drugs Ther,2005,19 (5):333-336.
  • 7Fiordaliso F,Chimenti S,Staszewsky L,et al.A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemiareperfusion injury[J].Proc Natl Acad Sci U S A,2005,102(6):2046 -2051.
  • 8Silverberg DS,Wexler D,Blum M,et al.The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe,resistant congestive heart failure improves cardiac and renal function and functional cardiac class,and markedly reduces hospitalizations[J].J Am Coll Cardiol,2000,35 (7):1737-1744.
  • 9Maggioni AP,Opasich C,Anand I,et al.Anemia in patients with heart failure:prevalence and prognostic role in a controlled trial and in clinical practice[J].J Card Fail,2005,11 (2):91-98.
  • 10Silverberg DS,Wexler D,laina A.The importance of anemia and its correction in the management of severe congestive heart failure[J].Eur J Heart Fail,2002,4(6):681-686.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部